Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 4/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606110 | 1.00 | LRRK2 (0.44) | LRRK2ERN1PGK1AAK1CHEK1 | |
| SCHEMBL26598664 | 0.85 | TTK (0.42) | LRRK2PGK1AAK1TTKAXL | |
| SCHEMBL26598600 | 0.84 | MKNK1 (0.42) | LRRK2AAK1CHEK1KCNH2TTK | |
| SCHEMBL26598688 | 0.83 | KCNH2 (0.46) | LRRK2KCNH2AXLFGFR1FGFR3 | |
| SCHEMBL26598660 | 0.83 | AXL (0.43) | CHEK1KCNH2TTKAXLACVR2A | |
| SCHEMBL26598628 | 0.82 | FGFR1 (0.45) | KCNH2AXLFGFR1FGFR2FGFR3 | |
| SCHEMBL31678779 | 0.82 | BRD4 (0.39) | KCNH2AXLFGFR1FGFR2FGFR3 | |
| SCHEMBL26598795 | 0.81 | FGFR1 (0.43) | TTKAXLFGFR1FGFR2FGFR3 | |
| SCHEMBL31678667 | 0.81 | FEN1 (0.43) | TTKFGFR1 | |
| SCHEMBL30606085 | 0.80 | IRAK1 (0.42) | CHEK1AXLS1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-4511366-A1 | KIT INHIBITORS | Blueprint Medicines Corporation (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-2776417-B1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECH LTD (GB) | 2018-10-31 | — | — | EP | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-9765059-B2 | 5-(Pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-10-20 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-9403797-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-08-02 | — | — | US | disclosed |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040540-B2 | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-23 | — | — | US | disclosed |
| WO-2013068755-A1 | 5-(PYRIDIN-2-YL-AMINO)-PYRAZINE-2-CARBONITRILE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | LRRK2 1274/4885ERN1 1008/4885PGK1 1528/4885 |
| US-20160304493-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | LRRK2 630/4885ERN1 1355/4885PGK1 145/4885 |
| US-20150225372-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | LRRK2 630/4885ERN1 1355/4885PGK1 145/4885 |
| US-20140315925-A1 | 5-(Pyridin-2-yl-Amino)-Pyrazine-2-Carbonitrile Compounds and Their Therapeutic Use | CHEK1, CHEK2, PLK1 | LRRK2 630/4885ERN1 1355/4885PGK1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.